Safety, Immunogenicity, and Efficacy of R21/Matrix-M and ChAd63/MVA-ME-TRAP in the Context of Controlled Human Malaria Infection: A Phase IIb Trial in Kenyan Adults

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 25 Feb 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs ME-TRAP malaria DNA vaccine Okairos (Primary) ; R 21 (Primary) ; Malaria vaccine live unattenuated-Sanaria; Malaria vaccine live unattenuated-Sanaria
Indications Falciparum malaria
Focus Adverse reactions; Pharmacodynamics

20 Feb 2025 According to ClinicalTrials.gov: US National Institutes of Health, Status changed from recruiting to discontinued.
19 Aug 2022 Planned End Date changed from 1 Nov 2022 to 1 Apr 2023.
19 Aug 2022 Planned primary completion date changed from 1 Nov 2022 to 1 Apr 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com